CAR T-Cell Therapy muChina
CAR T Cell kurapa muChina is progressing remarkably and has the potential to revolutionize cancer treatment. China is now a pioneer in this industry thanks to its strong regulatory framework and research infrastructure, which have fueled its development.
CAR T Cell therapy in China is available for 40,000 USD. Furthermore, China’s enormous patient population offers a special benefit for carrying out kliniki miedzo and compiling data.
China’s efforts are influencing the future of precision medicine uye nekupa tariro nyowani kune varwere vegomarara pasi rese sekufambira mberi kweCAR T-cell kurapwa.
Chii chinoita kuti CAR T Cell Therapy muChina Ive yakakosha?
CAR T-cell therapy in China is a significant advancement in cancer treatment and has given patients who previously had few options new hope. This innovative therapy has gained prominence in China, where over 700 ongoing kliniki miedzo are exploring ways to enhance its effectiveness and safety.
China has emerged as a pioneer in this field, showcasing a strong dedication to medical research and advanced patient care. The science behind CAR T Cell kurapwa for cancer in China involves modifying a patient’s own immune cells to recognize and attack cancer cells. This is achieved through genetic engineering, where the patient’s T cells are equipped with a chimeric antigen receptor (CAR) that targets cancer-specific mapuroteni. T cells are removed from the patient, genetically modified in a laboratory, and then infused back into the patient’s body to attack kenza.
CAR T cell kurapa for cancer in china has been effective in treating a variety of cancers, and continuing research continues to refine and broaden its applicability. With commercial applications such as Yescarta and Relma-cel, the future of CAR T-cell treatment in China is bright, with major market growth projected and domestic players making substantial breakthroughs. The journey from clinical trials to commercial applications reflects the dedication to advancing medical science for the benefit of cancer patients in China.
CAR T Cell Therapy muChina Iri Kupfuura US MuCancer Solutions!
China Iri Kutonga Sei Makiriniki Miedzo?
Kubva muna Ndira 2024, kune anopfuura mazana manomwe miedzo yekiriniki iri kuitika muzvipatara zvakasiyana muChina iyo yakatarisana nekuvandudzwa kweCAR T Cell therapy. Kubva 700 hurumende yeChina yakaisa mari yakawanda munzvimbo yebiotechnology, uye mhedzisiro yacho inowandisa. China yakabuda senzvimbo yekutsvagisa cancer, kunyanya mumunda weCAR-T cell therapy yegomarara muChina. Zvidzidzo zvekiriniki izvi, zvakaitwa nemasangano ane mukurumbira, zviri kufambira mberi zvakanyanya mukurapa marudzi akasiyana egomarara. CAR T cell therapy yeleukemia muChina, CAR T Cell Therapy ye lymphoma uye BCMA-yakavakirwa CAR T Sero kurapwa kweyakawanda myeloma muChina mamwe marudzi makuru ari kuwana mhinduro dzakanaka muzviedzo.
Semuyenzaniso, chipatara chePeking University Cancer Hospital muBeijing, China chakaratidza zvibereko zvakanaka mukurapa kudzokazve kana kuramba acute lymphoblastic leukemia (ALL) neCAR-T masero, zvichipa nzira yekurarama kuvarwere vane sarudzo shoma.
Chinonyanya kutariswa hachisi pagomarara reropa chete; China iri kutarisa zvakare muCAR-T cell therapy yemamota akasimba, ayo akambonetsa kurapa. Kukunda iyo yakaoma immune-yakadzvanywa mamiriro aripo mumamota, akangwara mazano ari kushandiswa kuvandudza CAR-T cell kushanda.
Kudyidzana nedzimwe nyika kunoita basa rakakosha mukubudirira kweChina, nevatsvaguri vekuChina vachidyidzana pasi rose kupanana hunyanzvi. Kufamba uku kunogona kushandura CAR T muChina, ichipa imwe nzira iri nyore uye inodhura.
Ndechipi Chiyero cheCAR-T Therapy muChina?
Kushandiswa kwechimeric antigen receptor (CAR) T-sero kurapwa mukurapa hematological malignancies kwave kunoshamisa kushanda. Kushandiswa kweCAR T-cell kurapwa kwakura muChina mumakore mapfumbamwe apfuura.
Yekutanga CAR T cell yekiriniki zvidzidzo zvakatanga muna 2013, uye pakasvika 2017 pakanga paine akawanda CAR T cell miedzo yekiriniki kupfuura nakare kose. Munguva pfupi yapfuura, China yakazivisa kuti yaizopa mari inosvika mabhiriyoni mazana maviri nemakumi matatu nemanomwe emadhora emari yemabhizinesi ekurapa maseru muna 237, inomiririra kuwedzera kukuru kwenhamba yemiedzo yekiriniki uye mapurojekiti akakosha ekutsvagisa anosanganisira masero eCAR T.
Rutsigiro rwakasimba rwehurumende, kupinda kwemari, kudiwa kwevarwere kwakanyanya, hurongwa hwekuchengetedza hutano hwakasiyana, uye kuedza kwevanachiremba veChinese nemasainzi zvese zvakabatsira mukuvhiya uku kwakakosha mukuita muChina.
CAR T-Cell kurapa maitiro
CAR T Cell Therapy yemultiple myeloma muChina, pamwe nedzimwe mhando dzegomarara reropa, imhando yemhando yepamusoro yekudzivirira zvirwere inosanganisira kurongazve masero emuviri ekudzivirira emuviri kuti atarise uye abvise maseru egomarara. Iyo CAR T cell process inowanzo sanganisira akati wandei akakosha matanho:
Kuunganidza Sero (Apheresis):
Tsika yekuunganidza T masero emurwere, rudzi rwesero rekudzivirira zvirwere, inozivikanwa seapheresis. Munguva yeapheresis, ropa rinounganidzwa kubva kumurwere uye muchina unoparadzanisa masero eT. Ropa rasara rinobva radzorerwa mumuviri womurwere. T masero anounganidzwa kubva muropa achishandisa chubhu inopinzwa mutsinga yeruoko. Izvi zvinotora maawa mashoma.
Genetic Shanduko:
Masero eT anogadziridzwa genetically mulabhu kuratidza Chimeric Antigen Receptor (CAR) pamusoro pavo. Iyo CAR yakarongerwa kuziva mapuroteni chaiwo, kana maantigen, anowanikwa pamusoro pemasero egomarara.
Kuwedzera Masero:
Masero eT akagadziridzwa anozorimwa owedzerwa, zvichiita kuti pave nenhamba yakawanda yemasero eCAR T. Iyi nzira inovimbisa kuti kune akagadziridzwa T masero anowanikwa kuti arapwe.
Conditioning (Lymphodepletion):
Varwere vanowanzoiswa kurapwa kwekugadzirisa pamberi peCAR T-cell infusion, iyo inogona kusanganisira yakaderera-dose chemotherapy kana radiation. Iyi conditioning inobatsira kugadzira nharaunda umo masero eCAR T achangobva kuisirwa anogona kuwanda nekushanda mukati memuviri wemurwere.
Kuiswa kweCAR T-Masero:
Kana agadzirwa, masero eCAR T anoiswazve muropa remurwere kuburikidza nedrip. Iwo akaisirwa CAR T maseru anobva atenderera nemuviri wese, achitsvaga nekusunga kumasero egomarara anoratidza antigen yakanangwa.
Kutarisa uye Kuuraya Masero eCancer:
Kana sero reCAR T rasangana nekenza yesero rine antigen yakakodzera, inosungirira kune cancer cell. Kudyidzana uku kunomutsa CAR T cell, zvichiita kuti ibudise mamorekuru anouraya cancer cell.
Response Monitoring:
Varwere vanotariswa zvakanyanya kune chero zviratidzo zvekupindura, kusanganisira kuderedzwa kwehukuru hwemamota. Kubudirira kweCAR T-sero kurapwa kunoongororwa uchishandisa akasiyana ekufungidzira uye kuyedza marabhoritari.
Kugadzirisa Side Effects:
Vamwe varwere vanogona kunge vaine cytokine release syndrome (CRS) kana neurotoxicity, iyo inotariswa zvakanyanya nenyanzvi dzehutano.
Maitiro Ekunyorera YeCAR T-Cell Therapy muChina?
Tumira mishumo yako
Tumira mishumo inotevera inosanganisira pfupiso yekurapa, Mishumo yeropa, Biopsy, Yazvino PET Scan, Bone marrow biopsy (Kana iripo) ku info@cancerfax.com kana WhatsApp pa +1-213 789-56-55
Ongororo & Maonero
Kana timu yedu yangogamuchira marepoti ako ekurapa, tinoaongorora toatumira kuzvipatara zviri kuita CAR T-Cell therapy nerudzi irworwo rwegomarara nechimaka. Isu tinotumira mishumo kune ane hanya nyanzvi uye tinowana maonero ake. Tinowanawo fungidziro kubva kuchipatara pakurapwa kwakakwana.
Medical visa uye kufamba
Kana ukangosarudza kushanyira kurapwa, tinoronga tsamba yevhiza yekurapa uye mamwe magwaro anodiwa kubva kuchipatara. Kana vhiza yagadzirira isu tinobatsira uye nekukutungamira mukugadzirira matikiti ekufamba uye endege.
Kurapa uye kutevera
Mumiriri wedu acharonga kugadzwa kwachiremba uye kuzadzisa zvigadziro zvinodikanwa zvekunyoresa kwauri. Achakubatsirawo nekupinzwa muchipatara uye nerumwe rubatsiro rwenzvimbo nerutsigiro rwunodiwa. Mushure mekunge kurapwa kwapera ticharonga kubvunza kwako kwekutevera nachiremba anorapa.
Sei China iri iyo Yakanakisa Sarudzo?
Clinical Miedzo & Advance Research
Neanopfuura mazana manomwe arikuenderera mberi nemiedzo yekiriniki paCAR T-Cell kurapwa kwegomarara muChina yawana matanho makuru. Innovative CAR T-cell therapies yakave yakashinga kugadzirwa uye kuyedzwa nevatsvagiri vekuChina uye masangano ekurapa, nekutarisa kune ese akasimba bundu uye hematological malignancies. Panyaya yeCAR T cell therapy kusimukira, China yanga iri muvanguard, uye akawanda ekucheka-kumucheto miedzo yekiriniki iri kuitika ikoko. Nekuda kweizvi, varwere vari kutsvaga kuwana zvichangobva kuitika muCAR T cell therapy vanogona kuwana China seimwe nzira inofadza.
Mutengo Uye Kuwanikwa
Mari yeCAR T-Cell yekurapa muChina yakaderera zvakanyanya pane iyo munyika dzakaita seUS, UK, Australia, Japani, Korea, uye Singapore. Kurapa kweCAR T-Cell kuChina kunogona kuita madhora makumi matanhatu chete. China ine yakaenzana kuwanikwa kweCAR T cell kurapwa kwegomarara muChina. Panogona kunge paine nguva pfupi dzekumirira kurapwa iko zvino sezvo nzvimbo dzakawanda dzekurapa muChina dzawana mvumo yekupa CAR T cell therapy. Pamusoro pezvo, CAR T cell therapy inowanzo kudhura muChina kupfuura kune dzimwe nzvimbo, seUnited States. Ichi chinhu chinogona kunyanya kukosha kune vanhu vari kutsvaga kurapwa kunokwanisika.
Nyanzvi Uye Zvakaitika
Nekuda kwekupinda kwayo muzviedzo zvekiriniki nekurapa kwakawanda, China yakagadzira ruzivo rwakakura uye ruzivo mukupa CAR T cell therapy yeleukemia muChina nyanzvi dzekurapa dzekuChina dzakavandudza ruzivo rwavo rweCAR T-sero therapy matambudziko uye kugona kwavo vatungamirire kuvandudza mhedzisiro yevarwere. China inopa hutano hwemhando yepamusoro nekuda kwehuwandu hwayo hwevarwere, zvivakwa zvinotsigira, uye ruzivo rwakaunganidzwa muCAR T cell kurapwa kwegomarara muChina.
Makambani MuUS Kudyidzana neChinese Makambani
Mumakore achangopfuura, mabhizinesi emuAmerica akatanga kushandira pamwe nevamwe vavo vekuChina kugadzira mishonga yemasero eCAR T. For ex. Muna 2015, WuXi AppTec, sangano rekuChina rekutsvagisa chibvumirano (CRO), uye Juno Therapeutics, bhizinesi reUS-based biopharmaceutical, vakabatana zvine hungwaru. Chinese biopharmaceutical kambani Cellular Biomedicine Group yakashanda neUS biopharmaceutical kambani Celgene, inova chikamu cheBristol-Myers. Squibb. Chibvumirano chekudyidzana pasi rose nerezinesi chakaitwa pakati peJanssen Biotech, femu yemishonga yaJohnson & Johnson, neLegend Biotech, bhizinesi rinoshanda muChina neUS.
Vanachiremba Vepamusoro VeCAR-T Therapy MuChina
Tora nyanzvi yechipiri maonero paCAR T-Cell therapy infusion kubva kune vakanyanya tsvagiridzo muChina.
Prof. Peihua Peggy Lu, (MD)
Medical Executive President weLu Daopei Hospital, Beijing, China , Zvakaitika: 27 Makore
Dr Zhao Defeng, (MD)
Mutungamiriri, Dhipatimendi reHematology, Beijing Gobroad Hospital, Zvakaitika: 24 Makore
Dr. Zhao Defeng ndiye Mutungamiriri weDhipatimendi reHematology paGaobo Medical (Hematology) Beijing Research Center, Beijing Gaobo Boren Hospital, nyanzvi mune zvehematology muWard Nine. Ane chigaro cheAssociate Chief Physician uye ane dhigirii reMasters kubva kuSecond Military Medical University. Dr. Defeng ane ruzivo nevarwere vanopfuura 1000 vanopa CAR T-cell therapy uye vane zvinopfuura makumi maviri nenhatu zvinoramba zvichiedzwa pakiriniki pairi. Anoonekwa semumwe wevana vanachiremba vepamusoro veCAR T-cell therapy muChina.
Zvipatara Zvepamusoro Zvekurapa kweCAR T MuChina
Peking University Cancer Hospital
Iyo innovative immunotherapy nzira inozivikanwa seCAR T-cell therapy yakaratidza vimbiso yakasarudzika mukurapa kwakasiyana siyana. Beijing, China Peking University Cancer Hospital yave mutungamiri wepasi rose mukuvandudza kurapwa kweCAR T-cell. Nerubatsiro rwechikwata chavo chemultidisciplinary, icho chine oncologists, immunologists, uye geneticists, kurapwa kwegomarara remunhu kwakakwira zvakanyanya. Peking University Cancer Hospital yakawana mibairo yakatanhamara muvarwere vane hematological malignancies nekushandura T masero evarwere kuratidza chimeric antigen receptors (CARs). Uku kurapwa-kumucheto kunopa varwere vegomarara tariro nyowani uku vachishandura munda we oncology uye kukwidza huwandu hwekupona.
Beijing Gobroad Boren Hospital
Nyanzvi ine mukurumbira ine makumi matatu emakore emukati mekiriniki uye ruzivo rwemurabhoritari, ichinyanya kutarisisa pane iyo domain yehematology. Dhipatimendi rinopa huwandu hwekuongorora uye kurapa masevhisi ezvirwere zvinokanganisa hematological system, senge multiple myeloma, leukemia, lymphoma, thalassemia, coagulation kusagadzikana, uye hematological tumors. Iyo inyanzvi muzvirongwa zvekurapa zvega uye zvakabatanidzwa kuongororwa kwezvirwere zvehematological. Nzira dzekurapa dzehematologic tumors dzinosanganisira chemotherapy, immunotherapy, yakanangwa kurapa, demethylation, uye radiotherapy. Uyezve, kuitira kuti tive nechokwadi chekuchengetedza uye kushanda kwekushandisa kwemishonga, vashandi vedu vezvokurapa vanogadzirisawo madosi zvichienderana nemishonga metabolism genotype maitiro uye kutarisa kushandiswa kwezvinodhaka.
Chipatara cheLu-Daopei
Beijing, Chipatara chekuChina cheLu Daopei chakasimudzira zvakanyanya ndima yeCAR T-cell kurapwa. Chipatara cheLu Daopei, icho chinoisa pamberi pekurapa cancer nekutsvagisa, yanga iri pamberi pekushandisa CAR T-cell therapy kurapa hematological malignancies. Oncologists, immunologists, uye geneticists pachikwata chavo vakazvipira kupedza miedzo yekiriniki nekugadzira murwere-chaiwo CAR T-cell therapy. Chipatara cheLu Daopei chaona kuvandudzwa kunokurudzira mumhedzisiro yevarwere uye huwandu hwekupona nekuda kweruzivo uye zvivakwa zvekucheka. Basa ravo rinoramba richikanganisa mabatirwo egomarara, richivhura mikana mitsva yevarwere vanoda tariro. Parizvino, vanoti vakaita zvinopfuura chiuru CAR T-Cell therapy infusions.
Chipatara Chekutanga Chakabatana, Zhejiang University Chikoro cheMishonga, Hangzhou
The First Affiliated Hospital, Zhejiang University School of Medicine yakavambwa muna 1947. Ndicho chipatara chekare chakabatana cheZhejiang University, boka rekutanga reInstitutions kuvaka "pamusoro-pamwero" nzvimbo dzekurapa dzenyika, National Medical Center yeZvirwere Zvinotapukira, Inotungamira Institution. Kuvaka National-Level Co
Yekutanga Yakabatana Chipatara, Zhejiang University Chikoro cheMishonga webhusaiti
Yekutanga Yakabatana Chipatara cheZhengzhou University
Mumunda weCAR T-cell kurapwa, Chekutanga Affiliated Hospital yeZhengzhou University, iri muZhengzhou, China, rave sangano rinozivikanwa. Chipatara ichi chafambira mberi zvikuru mukuwedzera kugona kweCAR T-cell therapy kuvarwere nekuisa simbiso huru pakurapa kwegomarara. Oncologists, immunologists, geneticists, uye dzimwe nhengo dzevashandi vavo vekurapa vakasiyana vese vakatora chikamu chinoshanda muzvidzidzo uye miedzo yekiriniki. Nzvimbo iyi yakarapa hematological malignancies nekubudirira kunoshamisa nekuda kwekushandiswa kweCAR T-cell therapy. Sezvo kurapwa kwegomarara kwemunhu kuchikura, The First Affiliated Hospital yeZhengzhou University iri pamberi, ichipa varwere tariro nyowani uye hupenyu huri nani.
CAR T-Cell kurapwa mutengo muChina
Ngatitarisei zvakanyanya pane cost of CAR-T cell therapy muChina. Kazhinji inotangira pamadhora makumi mana nemashanu kusvika pamakumi masere ezviuru. Mutengo weFUCASO (BCMA based CAR T-Cell therapy for multiple myeloma) inodhura madhora mazana maviri emadhora. Asi ramba uchifunga kuti idzi ingori fungidziro dzakaomarara, uye mutengo chaiwo unoenderana nezvimwe zvinhu zvishoma. Rudzi rweCAR-T kurapwa, kuoma kwekurapa, mari yechipatara, kutarisirwa kwakawedzerwa, uye kuongororwa zvese zvinogona kukanganisa mutengo wekupedzisira. Ramba uchifunga kuti nhamba idzi dzinogona kuchinja zvichienderana nehutano hwako. Kuti ubatsire kugadzirisa mitengo iyi, unofanirwa kuonana neboka rako rehutano. Vanogona kukupa ruzivo rwakanyanya rwemunhu. Iwe unofanirwawo kutarisa kuti uone kana inishuwarenzi yako inoivhara kana kana chero zvirongwa zvekubatsira mari zviripo. Izvi zvinokutendera kuti uite sarudzo dzakanakisa dzekurapa kwako uye bhajeti yako.
Chii chinonzi CAR T-Cell Therapy?
Chimeric antigen receptor T-cell therapy, inowanzozivikanwa seCAR T-cell therapy, ivhu-inoputsa immunotherapy iyo yakashandura zvachose nzira iyo kenza inorapwa. Inopa varwere vane mamwe magomarara tariro yaimboonekwa seisingarapike kana kuti ine nzira shoma dzekurapa.
Kurapa uku kunosanganisira kushandisa masero emuviri emuviri wemurwere-kunyanya, T masero-uye kuachinja-chinja kuvandudza kugona kwavo kuona nekuparadza maseru egomarara. Kuti aite izvi, masero eT anopihwa chimeric antigen receptor (CAR), iyo inovapa kugona kunanga mamwe mapuroteni, kana maantigen, pamusoro pemasero egomarara.
Masero eT kubva kumurwere anotanga kubviswa, uye anobva agadziriswa genetically kuratidza CAR. Murabhoritari, masero akachinjwa aya anowanzwa kuti abudise huwandu hwakati wandei hwemasero eCAR T, anozodzoserwa muropa remurwere.
Pavanenge vari mukati memuviri, masero eCAR T anowana masero ekenza anoratidza antigen inodiwa, anonamatira paari, uye anokonzera simba rekudzivirira zvirwere. Masero eCAR T akabatiswa anowedzera uye anoita kurwisa kwakanangana nemasero egomarara, achiauraya.
Ko CAR T-Cell Therapy Inoshanda Sei?
Kana ichishandiswa kurapa zvimwe zvirwere zveropa senge acute lymphoblastic leukemia (ALL) uye mamwe marudzi e lymphoma, CAR T cell therapy ye lymphoma kuchina yakaratidza mhedzisiro. Yakaburitsa mhinduro dzinozivikanwa uye mune vamwe varwere, kunyangwe kuregererwa kwenguva refu.
CAR T-cell therapy, zvisinei, inzira yakaoma uye yakasarudzika yekurapa inogona kuve nenjodzi nemhedzisiro yakaipa. Cytokine release syndrome (CRS), yakapararira immunological reaction iyo inogona kukonzera zviratidzo-sefuruwenza uye, mumamiriro ezvinhu akaipisisa, kutadza kwenhengo, kunogona kuitika kune vamwe vanhu. Pakave zvakare nemishumo yezvinokonzeresa neurological yakashata, zvisinei iyo inowanzorapika.
Zvisinei nematambudziko aya, CAR T-cell therapy ibudiriro huru mukurwisa gomarara uye inoratidza kugona kukuru kweramangwana. Zvidzidzo zvazvino zvinonangana nekusimudzira kushanda kwayo uye kuchengetedza chimiro pamwe nekuwedzera mashandisiro ayo kune akasiyana marudzi egomarara. CAR T-cell therapy inogona kushandura chiso chekurapa cancer uye kupa varwere kwese kwese tariro itsva nekumwe kufambira mberi.
Rudzi urwu rwekurapa runosanganisira kushandura masero eT emurwere, rudzi rwesero rekudzivirira, murabhoritari kuitira kuti vasunge nekuuraya maseru egomarara. Chubhu inotakura ropa kubva mutsinga iri muruoko rwomurwere kuenda kune imwe apheresis (isina kuratidzwa), iyo inobvisa masero machena eropa, kusanganisira T masero, uye inodzorera ropa rasara kumurwere.
Masero eT anobva agadziridzwa murabhoritari kuti ave nejene reiyo yakasarudzika inozivikanwa sechimeric antigen receptor (CAR). Masero eCAR T anowanzwa murabhoritari asati apinzwa mumurwere akawanda. Iyo antigen pamasero ecancer inogona kuzivikanwa neCAR T masero, ayo anobva auraya maseru egomarara.
Nderupi Rudzi RweCancer Inogona Kurapwa NeCAR-T Cell Therapy?
Varwere chete vane B-cell vasiri lymphoma Hodgkin's kana pediatric acute lymphoblastic leukemia vakamboedza nzira mbiri dzekare dzisina kubudirira vanogona kushandisa zvigadzirwa zveCAR T-cell therapy izvo zvakagamuchirwa neFDA. Nekudaro, CAR T-cell therapy yave kuedzwa muzvidzidzo zvekiriniki seyekutanga kana yechipiri-mutsara kurapwa kwevakuru lymphoma uye yevana acute lymphoblastic leukemia. Munguva pfupi yapfuura, zvimwe zvezvidzidzo zvakaratidza budiriro inoshamisa muzviitiko zvemamota akasimba senge glioblastoma, gliomas, kenza yechiropa, kenza yemapapu, kenza yeGI, kenza yepancreatic, uye kenza yemuromo.
Izvi zvinomiririra kufambira mberi kwakakosha mukutarisira kweleukemia uye B-cell lymphoma. Uyezve, inopa tariro kune avo vaimbofanotaurwa kuti vaizogara mwedzi mitanhatu chete. Zvino zvataona nzira dzekuramba uye nekugadzira mamwe matekiniki ekuzvirwisa, ramangwana rinoita serinonyanya kuvimbisa.
Bata nevatapi vedu vane ruzivo rwakanyanya pano pa CancerFax kubvunzurudzwa kwemahara kugadzira chirongwa chekuchengetedza chakakodzera chezvinodiwa zvehutano hwako. Ndokumbira utumire marepoti ako ekurapa ku info@cancerfax.com kana WhatsApp pa + 1 213 789 56 55.
Ndezvipi Zvakanakira zveCAR-T Cell Therapy?
Chakanyanya kubatsira ndechekuti CAR T-cell therapy inongoda kuisirwa kamwe chete uye kazhinji inongoda mavhiki maviri ekuchengetwa kwevarwere. Varwere vane non-Hodgkin lymphoma uye vana leukemia vachangobva kuongororwa, kune rumwe rutivi, vanowanzoda. chemotherapy kweinenge mwedzi mitanhatu kana kupfuura.
Zvakanakira zveCAR T-cell therapy, iri mushonga mhenyu, inogona kuramba iripo kwemakore mazhinji. Kana uye kana kudzokazve kukaitika, maseru anozokwanisa kuona uye kunanga maseru egomarara nekuti anogona kurarama mumuviri kwenguva yakareba.
Kunyange zvazvo ruzivo ruchiri kusimukira, 42% yevarwere vakuru ve lymphoma vakawana CD19 CAR T-cell kurapwa vakanga vachiri mukuregererwa mushure memwedzi gumi nemishanu. Uye mushure memwedzi mitanhatu, zvikamu zviviri muzvitatu zvevarwere vane acute lymphoblastic leukemia vakanga vachiri mukuregererwa. Nehurombo, varwere ava vaive nemamota ane hasha asina kurapwa nenzira yechinyakare yekuchengeta.
Ndeupi Rudzi Rwevarwere Rungave Vagashira Vakanaka veCAR-T Cell Therapy?
Varwere vari pakati pemakore matatu kusvika kumakore makumi manomwe vakaedza CAR T-Cell kurapwa kwemhando dzakasiyana dzegomarara reropa uye vakaonekwa kuti inoshanda zvakanyanya. Nzvimbo zhinji dzakati budiriro inopfuura 3%. Munhu anonyatsokwanisa kumirira CAR T-cell therapy panguva ino mwana ane acute lymphoblastic leukemia kana munhu mukuru ane B-cell lymphoma yakaoma uyo anga atova nemitsara miviri yekurapa kusingashandi.
Gore ra2017 risati rapera, pakanga pasina mwero wakagamuchirwa wekutarisira varwere vanga vatopfuura nemitsetse miviri yekurapa vasina kuwana kuregererwa. Mushonga chete wakatenderwa neFDA kusvika parizvino waratidza kubatsira zvakanyanya kuvarwere ava ndeyeCAR T-cell therapy.
Inoshanda Sei CAR-T Cell Therapy?
CAR T-cell therapy yave inoshanda zvikuru mukurapa mamwe marudzi egomarara reropa, seacute lymphoblastic leukemia (ALL) uye asiri Hodgkin lymphoma. Mumakiriniki ekuedzwa, mazinga ekupindura ave akanaka kwazvo, uye varwere vazhinji vakapinda mukuregererwa kwakakwana. Mune zvimwe zviitiko, vanhu vakanga vaedza mimwe mishonga yose vaiva nekuregererwa kwenguva refu kana kuti kurapa kunobvira.
Chimwe chezvinhu zvakanakisa nezveCAR T-sero kurapwa ndechekuti inonangana nemasero akakodzera. Iwo maCAR receptors akawedzerwa kumasero eT anogona kuwana chaiwo mamaki pamasero egomarara. Izvi zvinoita kuti zvikwanise kupa kurapa kwakanangwa. Iyi nzira yakanangwa inokuvadza maseru ane hutano zvishoma sezvinobvira uye inodzikisa njodzi yemhedzisiro inouya nemishonga yechinyakare senge chemotherapy.
Asi zvakakosha kuyeuka kuti CAR T-cell therapy ichiri nzvimbo itsva ichiri kuchinja. Vatsvagiri uye vanachiremba vari kushanda nesimba kuti vagadzirise matambudziko akaita semutengo wakakwira, mukana wemhedzisiro yakakomba, uye chokwadi chekuti inongoshanda kune mamwe marudzi egomarara.
Pakupedzisira, CAR T cell therapy yemultiple myeloma kuChina yakaratidza kuva nzira yakabudirira zvikuru yekurapa gomarara iri. Kunyangwe iri nzira inovimbisa uye ine simba, zvidzidzo zvakawanda uye miedzo yekiriniki inodiwa kuivandudza nekutsvaga nzira nyowani dzekuishandisa. CAR T-cell therapy inogona kushandura marapirwo egomarara uye kuita kuti zvinhu zvirinani kuvanhu pasi rose kana ikaramba ichipora.
Kusanganisa Maitiro eCAR T-Cell Therapy:
- Varwere vane CD19+ B-cell Lymphoma (Angangoita maviri asati asangana chemotherapy regimens)
- Kuve nezera 3 kusvika 75 makore
- ECOG zvibodzwa ≤2
- Vakadzi vane mikana yekubereka vanofanira kunge vaine weti pamuviritest yakatorwa uye yakaratidza kuti haina kunaka musati marapwa. Vose varwere vanobvumirana kushandisa nzira dzakavimbika dzekudzivirira pamuviri panguva yekuedzwa uye kusvika pakutevera kwenguva yekupedzisira.
Maitiro ekusabatanidzwa eCAR T-Cell Therapy:
- Intracranial hypertension kana kusaziva
- Kukundikana kwekupempa
- Yakaparadzirwa intravascular coagulation
- Hematosepsis kana Kusadzora kunoshanda hutachiona
- Kusadzorwa chirwere cheshuga
CAR T-Cell Therapies Yakatenderwa neUSFDA
KYMRIAH
B-cell precursor acute lymphoblastic leukemia, yakadzokororwa kana refractory diffuse hombe B-cell lymphoma
Yese mhinduro mwero (CR):> 90%
Chinangwa: CD19
Price: $ 475,000
Nguva yekubvumidza: Nyamavhuvhu 30, 2017
YESCARTA
Kudzokororwa kana kudzoreredza kuparadzira hombe B-cell lymphoma, yakadzokororwa kana refractory follicular cell lymphoma.
Non-Hodgkin's lymphoma Yakazara mhinduro mwero (CR): 51%
Chinangwa: CD19
Price: $ 373,000
Nguva yekubvumidza: 2017 Gumiguru 18
TECARTUS
Kudzokororwa kana refractory diffuse hombe B-cell lymphoma
Mantle cell lymphoma Yakazara mhinduro mwero (CR): 67%
Chinangwa: CD19
Price: $ 373,000
Nguva Yakabvumirwa: Gumiguru 18, 2017
BREYANZI
Kudzokororwa kana refractory diffuse hombe B-cell lymphoma
Yese yekupindura mwero (CR): 54%
Chinangwa: CD19
Price: $ 410,300
Nguva Yakabvumirwa: Gumiguru 18, 2017
ABECMA
Yakadzokazve kana Refractory Multiple Myeloma
Yese yekupindura mwero: 28%
Chinangwa: CD19
Price: $ 419,500
Yakabvumirwa: Gumiguru 18, 2017
Ndeapi Madivi Migumisiro ECAR-T Cell Therapy?
Pazasi pane mamwe emhedzisiro yeCAR T-Cell therapy.
- Cytokine release syndrome (CRS): Iyo yakanyanya kupararira uye ingangove yakakosha mhedzisiro yeCAR T-sero kurapwa ndeye cytokine release syndrome (CRS). Zviratidzo zvakaita sefuruu, zvinosanganisira fivha, kupera simba, kutemwa nemusoro, uye kurwadziwa kwemhasuru, zvinounzwa nekugadziridzwa kweT cell 'kugadzirwa kwemacytokines. Mumamiriro ezvinhu akanyanyisa, CRS inogona kukonzera kupisa kwakanyanya, hypotension, kutadza kwenhengo, uye kunyange mhedzisiro inouraya.
- Neurological Toxicity: Vamwe varwere vanogona kukudziridza mhedzisiro yetsinga, iyo inogona kusimuka mukuomarara kubva kune zvishoma zvakakomba zviratidzo senge kuvhiringidzika kunyoro uye kuvhiringidzika kune zvakakomba zvakanyanya senge pfari, delirium, uye encephalopathy. Mushure meCAR T-cell infusion, neurological toxicity inowanzoitika mukati mevhiki yekutanga.
- Cytopenias: CAR T-sero kurapwa kunogona kukonzera kuderera kwemasero eropa, akadai seanemia (yakaderera masero matsvuku eropa), neutropenia (yakaderera masero eropa eropa), uye thrombocytopenia (yakaderera platelet count). Utachiona, kubuda ropa, uye kupera simba ndezvimwe zvezvipingamupinyi zvinogona kuwedzerwa ne cytopenias idzi.
- Zvirwere: Iyo CAR T-cell kurapa kudzvanyirira kwemasero ane hutano ekudzivirira muviri kunowedzera njodzi yehutachiona, hutachiona, uye fungal utachiona. Kudzivirira zvirwere, varwere vangada kunyatsotariswa uye kupiwa mishonga yekudzivirira.
- Tumor Lysis Syndrome (TLS): Mushure meCAR T-cell therapy, zvinokwanisika mune mamwe mamiriro ezvinhu kuti huwandu hwakawanda hwemukati hubudiswe muropa nekuda kwekukurumidza kuuraya kwebundu maseru. Izvi zvinogona kukonzera kusagadzikana kwemetabolism, senge yakawandisa potassium, uric acid, uye phosphate mazinga, izvo zvinogona kukuvadza itsvo uye kukonzera mamwe matambudziko.
- Hypogammaglobulinemia: CAR T-sero kurapwa ine mukana wekudzikisa antibody synthesis, izvo zvinogona kukonzera hypogammaglobulinemia. Izvi zvinogona kuita kuti utachiona hunoramba huchidzokororwa huwedzere uye zvinodaidzira kuenderera mberi kwemishonga yekutsiva masoja ekudzivirira chirwere.
- Organ toxicity: CAR T-cell therapy ine mukana wekukuvadza nhengo dzakawanda, kusanganisira moyo, mapapu, chiropa, uye itsvo. Izvi zvinogona kutungamira kune zvisina kujairika renal basa bvunzo, nyaya dzekufema, nyaya dzemoyo, uye kusakwana kwechiropa basa bvunzo.
- Hemophagocytic lymphohistiocytosis (HLH): Chirwere chisingawanzoitiki asi zvichida chinouraya chinouraya chinonzi hemophagocytic lymphohistiocytosis (HLH) chinogona kukura semugumisiro weCAR T-cell therapy. Inosanganisira kuwandisa kwemasero ekudzivirira muviri, izvo zvinokonzera kukanganisa kwakakomba kwenhengo uye kuzvimba.
- Hypotension uye Fluid Retention: Nekuda kweiyo cytokines iyo CAR T masero anoburitsa, vamwe varwere vanogona kukura yakaderera yeropa (hypotension) uye kuchengetwa kwemvura. Kugadzirisa zviratidzo izvi, matanho ekutsigira anosanganisira intravenous fluid uye mishonga inogona kudiwa.
- Secondary Malignancies: Mishumo yezvirwere zvechipiri zviri kubuda zvichitevera CAR T-cell therapy iripo, zvisinei nekushaikwa kwavo. Tsvagiridzo iri kuitwa parizvino pamusoro pekugona kwechipiri hutsinye uye njodzi dzenguva refu.
Zvakakosha kuyeuka kuti haasi murwere wese achava nemigumisiro iyi uye kuti nhanho yemunhu wega wega ichasiyana. Kuti uderedze uye uderedze izvi zvinokonzeresa zvinokonzeresa, timu yekurapa inotarisisa varwere pamberi, panguva, uye mushure meCAR T-cell therapy.
Time frame
Tarisa pazasi iyo yakazara nguva yakatarwa inodiwa kuti upedze iyo CAR T-Cell kurapwa maitiro. Nekudaro, iyo nguva yakatarwa inotsamira zvakanyanya kureba kwerabhoritari kubva kuchipatara yakagadzirira maCAR.
- Kuongorora & bvunzo: vhiki imwe
- Pre-kurapwa & T-Cell Kuunganidza: vhiki imwe
- T-Cell kugadzirira & kudzoka: mavhiki maviri kusvika matatu
- 1st Kubudirira kuongororwa: mavhiki matatu
- 2nd Effectiveness analysis: mavhiki matatu.
Yese nguva yakatarwa: 10-12 Mavhiki
CancerFax Inogona Kukubatsira Sei Kuti Uwane CAR T Cell Therapy?
Kana zvasvika pakusarudza mudiwa akakodzera parwendo rwako rwekurapa cancer, CancerFax inomira pachena sechiedza cherutsigiro uye hunyanzvi. Neruzivo rwakawanda mukupa CAR T-cell therapy, tinoona kukosha kwehutano hwako uye kukosha kwekuwana kutarisirwa kwakanyanya. Chii chinosiyanisa CancerFax iboka redu revashandi vehutano vakazvipira uye vane tsitsi vanoisa hutano hwako pamberi penguva yese yekurapa.
Isu tinotenda mukurapwa kwemunhu nekuti tinoziva kuti murwere wega wega akasiyana uye anoda kutarisirwa kwega. Kuzvipira kwedu kune kugona kunoratidzwa mukusarudzika kwakadzama kwenyanzvi dzine ruzivo rwakanyanya uye kubatana nezvipatara zvakawanda, kuve nechokwadi chekuti unowana sarudzo dzakanyatsokodzera zvaunoda pasina kupa mhando. Mumakore gumi apfuura, CancerFax yanga iri gwara rinovimbwa nevarwere kubva pamusoro penyika 8, uye isu takazvipira kuwedzera mwero wakafanana wekutarisira nerutsigiro kwauri. Bata nhasi kuti ugamuchire iyo yakanakisa CAR T Cell kurapwa muChina.
CancerFax yakabatana neiyo zvipatara zvekenza yepamusoro uye hematology muChina ndidzo nzvimbo dzakatenderwa dzeCAR T Cell therapy administration. Zvichienderana nemamiriro ekurapa uye emari yemurwere uye pedyo nekwaari kuenda, tinokumbira chipatara chakakodzera.
Mibvunzo Inonyanya Kubvunzwa
Ndedzipi mhando dzegomarara dzakakodzerwa neCAR T-Cell kurapwa muChina?
MuChina, CAR T-cell therapy inonyanya kubvumidzwa uye inoshandiswa kurapa hematologic malignancies, senge lymphoma, leukemia, uye myeloma.
Kunyangwe paine mimwe miedzo yekiriniki uye kuedza kwekutsvaga kutsvaga CAR T-sero kurapwa kwemamota akasimba, kufambira mberi munzvimbo iyi kwave kunonoka kana zvichienzaniswa nehematologic malignancies.
Sekureva kweruzivo rwuripo, CAR T-sero kurapwa kwemamota akasimba inotora 9% chete yeCAR T-sero kurapwa kuri kugadzirwa kuChina.
Kushanda kweCAR T Cell therapy kuChina kwakadii kana kuchienzaniswa nemamwe marapirwo?
Kubudirira kwechimeric antigen receptor T-cell (CAR-T) kurapa muChina kwakafananidzwa nemamwe marapirwo kuburikidza nemiedzo yakakura yekiriniki uye tsvakiridzo. Kubva muna 2022, China ine nhamba yakakura yeCAR-T zvidzidzo zvekiriniki kupfuura United States, kunyanya mune hematologic malignancies. Mishonga miviri yeCAR-T, axicabtagene ciloleucel (Yescarta) uye relmacabtagene autoleucel (Carteyva), yakatenderwa kuChina neNational Medical Products Administration (NMPA).
Kurapa kweCAR-T muChina kwakaratidza kushanda mune dzakasiyana siyana hematologic malignancies, kusanganisira B-cell acute lymphoblastic leukemia (ALL), lymphoma, uye multiple myeloma (MM). Nekudaro, matambudziko anoramba aripo, akadai semutengo wakakwira, maitiro ekugadzira anopedza nguva, uye zviitiko zvakashata zvine chekuita nekudzivirira. Kugadzirisa nyaya idzi, vaongorori veChinese vari kugadzira nzira dzekugadzirisa CAR-T kurapa, kusanganisira kugadzirwa kweallogeneic CAR-T zvigadzirwa uye kushandiswa kwemamwe madhizaini ekudhura.
Muchidimbu, kurapwa kweCAR-T muChina kwakaratidza mhedzisiro inovimbisa muhematologic malignancies, nenhamba yakakura yemakiriniki ekuedzwa kana ichienzaniswa neUnited States. Nekudaro, zvinonetsa zvinoramba zviripo, uye kumwe kutsvagisa kunodiwa kukwirisa kurapa uye kuwedzera kushandiswa kwayo kumamota akasimba.
Ndeapi mhedzisiro yakaonekwa kubva kuCAR T Cell kurapwa muChina?
MuChina, mhedzisiro inocherechedzwa kubva kuCAR T-cell therapy inosanganisira:
- Cytokine kuburitsa chirwere (CRS)
-Neurotoxicity kana zviitiko zvetsinga
- Zvirwere, kunyanya utachiona
B-kupera kwesero (aplasia)
- Hypogammaglobulinemia
- Cytopenia
Aya maside mhedzisiro haana ega kuChina asi akajairika muCAR T-cell therapy pasi rese. Kutarisira nekudzivirira kweaya maside mhedzisiro kwakakosha pakuona kuchengetedzwa kwemurwere uye nekugadzirisa mhedzisiro yekurapa.
Kurapa kweCAR T kunodhura zvakadii kuChina?
Kutorwa kwemari muzvitoro kweCAR-T cell therapies kuChina kunowanzo kutenderedza Chinese Yuan (CNY) 1,200,000, iyo yakaenzana neUS$170,000. Iko kudhura-kushanda kweCAR-T cell therapies muChina kunosiyana zvichienderana nekurapa kwacho uye mamiriro emurwere. Semuyenzaniso, iyo incremental cost-effectiveness ratio (ICER) yeAxicabtagene ciloleucel (Axi-cel) versus standard of care (SOC) yevarwere vane diffuse hombe B-cell lymphoma (DLBCL) mumutsara wechipiri (2L) yaive ingangoita. CNY 363,977 pagore-yakagadziriswa hupenyu gore (QALY). Zvisinei, marapirwo aya haaonekwe seanodhura mune chero-mutsetse marongero kune varwere veDLBCL paWorld Health Organisation's (WHO) -inokurudzirwa kuda-kubhadhara chikumbaridzo. Kuderedzwa kwemutengo kweCAR-T marapirwo inzira huru yekudzikisa maICER uye kuve nechokwadi chekuti mutengo wezvinodhaka unoenzana nerubatsiro rwehutano hwemurwere.
Pane here kuenderera mberi nemiedzo yekiriniki yekurapwa kweCAR-T muChina?
Ehe, kune arikuenderera mberi miedzo yekiriniki yeCAR-T cell therapy muChina. Kubva muna Ndira 2024 kune anopfuura mazana manomwe arikuenderera mberi miedzo yeCAR T Cell therapy muChina. China yakava nyika ine yakanyanya kunyoreswa CAR-T miedzo, uye maitiro aya akaenderera mberi kubva ipapo. Hurumende yeChina yakaisa mari yakawanda mukutsvagisa kweCAR-T, uye nyika ine nhamba huru yemiedzo yekiriniki netsvakiridzo mundima iyi. Iyi miedzo inowedzera huwandu hwekurapa kubva kuhematological malignancies kusvika kune sloid tumors uye mamwe matambudziko zvakare.
Ini ndinowana sei chipatara chepamusoro kana chiremba anopa CAR T-cell therapy muChina?
CancerFax inonzwisisa kukosha kwekusarudza nzvimbo yakanakisa uye nyanzvi yeCAR T cell kurapwa muChina. Sevhisi yedu yakazvipira yakanangana nekubatanidza vanhu vane yakanakisa kenza yekuchengetedza nemutengo unokwanisika. Isu tinoshanda kunyanya nezvipatara zvakatemerwa zvehematology nekenza muChina izvo zvakawana mvumo yekupa CAR T Cell therapy. Isu tinobatsira varwere kusarudza yakanakisa sarudzo maererano nezvavanoda uye zvavanoda.
Ndezvipi zvinodiwa kuti unzi unokodzera kurapwa kweCAR T- CELL kuChina?
Zvinodiwa zvekukodzera zveCAR T cell therapy kurapwa muChina zvinosiyana zvichienderana nekurapa chaiko uye mamiriro emurwere. Kazhinji, varwere vane hematological malignancies, senge lymphoma, leukemia, uye myeloma, ndivo vanonyanya kukwikwidza kuCAR T cell therapy muChina.
Varwere vanofanirwa kuve nekuongororwa kwemhando yegomarara uye vatadza kupindura kune zvakajairwa marapirwo, senge chemotherapy kana radiation therapy.
Pamusoro pezvo, varwere vanofanirwa kusangana nemamwe maitiro ehutano, sekuve nekuita nhengo yakakwana uye kusave nehutachiona hunoshanda kana zvimwe zvakakomba zvirwere zvinogona kukanganisa kurapwa. Maitiro ekukodzera kune yega yega kuyedzwa kwekiriniki anogona kusiyana, uye varwere vanofanirwa kusangana nezvinodiwa zvekuedzwa kuti vatore chikamu.
Kuti vaonekwe vanokodzera kurapwa neCAR T cell therapy kuChina, varwere vanofanirwa kuita mamwe maitiro. Maitiro aya anosanganisira CD19+ B-cell Lymphoma ine kanenge maviri asati asangana chemotherapy masesheni, zera remakore matatu kusvika 3 makore, uye ECOG mamakisi ≤75. Uyezve, kune varwere vechikadzi vane kugona kubereka, bvunzo yekuzvitakura inofanirwa kuitwa uye kuoneswa kuti haina kunaka kurapwa kusati kwatanga. Uyezve, varwere vose vanofanira kubvumirana kushandisa nzira yakavimbika yekudzivirira pamuviri panguva yekuedzwa uye kusvika pakutevera kwekupedzisira.
Pane here mitemo kana zvirambidzo zvevarwere vekunze vanoenda kuChina kunorapwa neCAR T cell therapy?
Hapana zvirambidzo zvakadaro kune varwere vekunze. Nekudaro, kugamuchira kurapwa kwakanyanya muChina kunoda kuwana mvumo kubva kune vekurapa uye vhiza yekurapa.
Inguva yakadii yatingatarisira kuona mhinduro kubva kuCar T-Cell kurapwa muChina?
Nguva yekuti varwere vaone mibairo kubva kuCAR T cell kurapwa muChina inogona kusiyana. Kazhinji, ma scans anoitwa mushure memavhiki maviri-2 kutarisa maitiro eCAR T cell therapy. CAR T cell therapy yakawana budiriro yakakura mukurapa hematological malignancies, uye China yave nyika inotungamira muCAR T kurapa kwekiriniki miedzo. Nekudaro, zvakakosha kuziva kuti mhedzisiro yeCAR T cell therapy inogona kusiyanisa kune mumwe nemumwe murwere, uye yakatarwa nguva yekuona mhedzisiro inogona kuenderana nezvinhu zvakaita semamiriro emurwere, rudzi rwegomarara riri kurapwa, uye chaiyo CAR T. cell therapy iri kushandiswa. Kunyange zvazvo kurapa kwakaratidza kunoshamisa kwekliniki migumisiro, kusanganisira yakakwirira yepamusoro-soro yemhinduro, nguva chaiyo apo murwere anogona kutarisira kuona migumisiro inogona kusatsanangurwa pasi rose uye inogona kusiyana kubva kune mumwe munhu kune mumwe munhu. Naizvozvo, zvinokurudzirwa kuti varwere vataurirane nevanopa hutano uye vaongorori vezvekuongororwa kwekiriniki kuti vawane ruzivo rwakakwana maererano nenguva inotarisirwa yekuona mhinduro kubva kuCAR T cell therapy.
Ko kurapwa kwenguva refu kwekutevera kana kutarisa kunodiwa kune varwere vakamborapwa neCAR T-Cell muChina?
Ehe, kurapwa kwenguva refu kwekutevera kana kutarisisa kunodiwa kune varwere vakaita CAR T cell therapy muChina. CAR T cell therapy yakaratidza zvinoshamisa mhedzisiro yekiriniki mukurapa kwehematological malignancies, asi inogona zvakare kuve nemhedzisiro inogona kuitika, senge cytokine release syndrome (CRS) uye neurotoxicity.
Naizvozvo, varwere vakawana CAR T cell therapy inoda kutariswa kwepedyo kwezvingangoitika mhedzisiro uye kwenguva refu yekutevera kuti vaone kusimba kwemhinduro uye inogona kudzoka kenza. Nguva yekutevera inogona kusiyana zvichienderana nerapiro chaiyo uye mamiriro emurwere, asi zvinowanzo sanganisira kugara uchiongororwa uye kuongororwa kwekufungidzira kutarisa hutano hwemurwere uye kuona chero kudzoka kwegomarara.
Pamusoro pezvo, varwere vangangoda rubatsiro rwerutsigiro, senge mishonga yekudzora mhedzisiro kana kumwe kurapwa kana gomarara rikadzoka.
Zvinoita here kubatanidza CAR T cell therapy nemamwe marapirwo akadai sechemotherapy, radiation, kana kuisirwa mwongo?
Hongu, zvinogoneka kubatanidza CAR T cell therapy nemamwe marapirwo akadai sechemotherapy, radiation, kana bone mwongo transplant. Pane kuwedzera kufarira mukubatanidza CAR T cell therapy nemamwe maanticancer agents kuti agadzirise migumisiro yekurapa, kunyanya mumamiriro ezvinhu ehematologic malignancies. Semuenzaniso, mumyeloma, misanganiswa inogona kusanganisira yakajairwa myeloma therapy yakapihwa mushure meCAR T-cell infusion senzira yekuchengetedza.
Pamusoro pezvo, musanganiswa weradiotherapy neCAR-T cell therapy yakaratidza zvinovimbisa mhedzisiro mukusimudzira chaiyo kusadzivirirwa uye kugadzira inoyevedza tumor microenvironment yeCAR-T maseru mumamota akasimba.
Uyezve, musanganiswa wechemotherapy neCAR-T cell therapy wakaongororwa senzira yekukunda zvipingamupinyi muCAR-T cell therapy uye nekupa synergistic mhedzisiro, kunyanya mukurapwa kwemamota akasimba. Idzi nzira dzemusanganiswa dzinovavarira kusimudzira kuchengetedzeka uye kushanda kweCAR-T cell therapy nekugadzirisa tumor microenvironment, optimize chimiro cheCAR, uye pamwe kunanga akawanda maantigen.
Ndeipi kufambira mberi kana zviitiko zviri kuitika muCAR T-cell therapy research mukati meChina?
KuChina, CAR T cell therapy tsvakurudzo iri kukurumidza kubuda, nenyika iine makiriniki akawanda eCAR T cell kubva muna 2017. Hurumende yeChina yakaisa mari yakawanda muCAR T cell therapy, uye nyika ine nhamba huru yemakiriniki ekuedzwa uye zvakakosha. tsvakurudzo munyaya iyi. Mishonga yeCAR T yesero yakatenderwa kurapa hematological malignancies, senge diffuse hombe B-cell lymphoma (DLBCL).
Vatsvagiri muChina vari kuongorora nzira dzakasiyana dzekugadzirisa CAR T cell therapy, kusanganisira kuvandudzwa kwezvivakwa zveCAR, marapirwo akasanganiswa nemamwe marapirwo, uye kushandiswa kwemasero eCAR T mumamota akasimba. Zvisinei, matambudziko anoramba aripo, akadai sekuoma kwekugadzira uye kutonga, kudhura kwakanyanya kwekurapa, uye kudiwa kwezvimwe zvine musoro uye zvepakutanga miedzo yekiriniki.
Zvisinei nekuvhiringwa kwemiedzo yekiriniki nekuda kwedenda reCCIDID-19, kutsvagisa kuri kuenderera mberi muChina, nesangano renyika, National Medical Products Administration (NMPA), rabvumidza marapiro maviri eCAR T chete seruzivo rwazvino rwuripo.
Ndeapi matanho akajairwa anobatanidzwa mukuenda kuChina kunorapwa neCAR-T-cell therapy?
Matanho akajairwa anowanikwa mukuenda kuChina kunorapwa neCAR T cell therapy anogona kusiyana zvichienderana nechipatara chaicho kana nzvimbo yekurapisa. Nekudaro, mamwe matanho akajairwa anogona kusanganisira:
1. Kutsvakurudza zvipatara kana nzvimbo dzekurapa muChina dzinopa CAR T cell therapy uye kusarudza imwe inosangana nezvido zvako.
2. Kubata chipatara kana nzvimbo yekurapisa kuti ubvunze nezve nzira yekurapa, kusanganisira mutengo, zvinodiwa pakukodzera, uye chero magwaro anodiwa.
3. Kutsvaga rubatsiro kubva kune mutarisiri wako wehutano uye kupa zvinyorwa zvekurapa kuchipatara kana nzvimbo yekurapwa.
4. Kunyorera vhiza rekurapwa kuti uende kuChina kunorapwa.
5. Kuzvirongera mafambiro uye pokugara iwe pachako uye chero nhengo dzemhuri dzinoperekedza.
6. Kuongororwa nachiremba uye kuongororwa pakusvika kuchipatara kana nzvimbo yekurapwa.
7. Kugamuchira CAR T cell therapy kurapwa uye nekuita chero chinodiwa chekutevera kutarisirwa.
8. Kudzokera kumba uye kuenderera mberi nekuchengetwa kwenguva refu kwekutevera uye kutarisa.
Zvakakosha kuziva kuti matanho chaiwo anowanikwa mukuenda kuChina kunorapwa neCAR T cell therapy anogona kusiyana zvichienderana nechipatara kana nzvimbo yekurapisa uye nemamiriro ezvinhu emurwere. Zvinokurudzirwa kuti varwere vataurirane nevanovapa zvehutano uye chipatara kana nzvimbo yekurapwa kuti vawane ruzivo rwakakwana maererano nemaitiro ekurapa uye zvinodiwa pakufamba.
CancerFax inokuchengetera matanho ese aya kuitira kuti urambe wakatarisa pakurapa isu tichichengeta zvimwe zvinhu zvese.
Ndeipi mwero wekubudirira kweCAR T muChina?
CAR T-cell therapy yakaratidza zvibereko zvakanaka mukurapa gomarara reropa kuChina. Kubva muna Ndira 2024, China yaive nemiedzo yekiriniki inoenderera mberi pasi rose yekuyedza CAR T-cell therapy, iine 337 yakatarisana negomarara reropa uye 111 pamamota akasimba. CAR T-cell therapy yakaderedza mapundu mu75.9% yevarwere velymphoma vane chirwere chakadzoka mushure mekunge marapirwo apfuura akundikana. Vanopfuura hafu (51.7%) yevarwere vakanga vasina mamota anooneka anotevera kurapwa. Gore rimwe gare gare, 76.8 muzana yevarwere ve lymphoma vakaramba vari vapenyu. China yakatendera marapiro maviri eCAR T-cell anonzi FKC876 neCarteyva ekurapa cancer. China iri kutungamira kutsvagisa nekusimudzira pasi rose muCAR T-cell therapy.